BACKGROUND: With improved cure rates of cancer in children and adolescents, the long-term effects of oncological treatment, including impaired fertility, have become an important clinical issue. METHODS: In 2008, we conducted a nationwide survey in Germany in which we asked 4689 female and male patients who had been treated for cancer in childhood or adolescence for information on menstruation, previous fertility testing (if any), attempts to conceive, and pregnancies. In a complementary study carried out in 2009, 748 former cancer patients in Berlin were offered hormone testing and sperm analysis. The defined criteria for suspected infertility were, in women, anti-muellerian hormone levels below 0.1 ng/mL; in men, FSH levels above 10 IU/L and inhibin B levels below 80 pg/mL, or azoospermia. RESULTS: The respondents to the nationwide survey included 1476 leukemia survivors and 1278 persons who had had a solid tumor. 104 former leukemia patients and 96 former solid tumor patients had already undergone fertility testing, leading to the suspicion of infertility in 26% and 34% of the persons in these respective groups (95% confidence intervals [CI], 18%-34% and 25%-43%). The patients who were tested in the Berlin study included 59 leukemia survivors and 104 persons who had had a solid tumor. The frequency of suspected infertility in these two groups was 25% and 27%, respectively (95% CI, 14%-36% and 18%-36%). CONCLUSION: Up to one-third of adults who undergo fertility testing after having been treated for cancer in childhood or adolescence have suspected infertility. Patients and their parents should be counseled about the possibility of infertility and about fertility-preserving measures.
BACKGROUND: With improved cure rates of cancer in children and adolescents, the long-term effects of oncological treatment, including impaired fertility, have become an important clinical issue. METHODS: In 2008, we conducted a nationwide survey in Germany in which we asked 4689 female and male patients who had been treated for cancer in childhood or adolescence for information on menstruation, previous fertility testing (if any), attempts to conceive, and pregnancies. In a complementary study carried out in 2009, 748 former cancerpatients in Berlin were offered hormone testing and sperm analysis. The defined criteria for suspected infertility were, in women, anti-muellerian hormone levels below 0.1 ng/mL; in men, FSH levels above 10 IU/L and inhibin B levels below 80 pg/mL, or azoospermia. RESULTS: The respondents to the nationwide survey included 1476 leukemia survivors and 1278 persons who had had a solid tumor. 104 former leukemiapatients and 96 former solid tumorpatients had already undergone fertility testing, leading to the suspicion of infertility in 26% and 34% of the persons in these respective groups (95% confidence intervals [CI], 18%-34% and 25%-43%). The patients who were tested in the Berlin study included 59 leukemia survivors and 104 persons who had had a solid tumor. The frequency of suspected infertility in these two groups was 25% and 27%, respectively (95% CI, 14%-36% and 18%-36%). CONCLUSION: Up to one-third of adults who undergo fertility testing after having been treated for cancer in childhood or adolescence have suspected infertility. Patients and their parents should be counseled about the possibility of infertility and about fertility-preserving measures.
Authors: R Rendtorff; C Hohmann; S Reinmuth; A Müller; R Dittrich; M Beyer; L Wickmann; T Keil; G Henze; A Borgmann-Staudt Journal: Klin Padiatr Date: 2010-05-31 Impact factor: 1.349
Authors: A Borgmann-Staudt; R Rendtorff; S Reinmuth; C Hohmann; T Keil; F R Schuster; W Holter; K Ehlert; P Keslova; A Lawitschka; A Jarisch; G Strauss Journal: Bone Marrow Transplant Date: 2011-04-11 Impact factor: 5.483
Authors: Ralf Dittrich; Andreas Mueller; Helge Binder; Patricia G Oppelt; Stefan P Renner; Tamme Goecke; Inge Hoffmann; W Matthias Beckmann Journal: Dtsch Arztebl Int Date: 2008-04-11 Impact factor: 5.594
Authors: Michael von Wolff; Jacques Donnez; Outi Hovatta; Victoria Keros; Theodoris Maltaris; Markus Montag; Bruno Salle; Murat Sonmezer; Claus Yding Andersen Journal: Eur J Cancer Date: 2009-03-04 Impact factor: 9.162
Authors: Daniel M Green; Charles A Sklar; John D Boice; John J Mulvihill; John A Whitton; Marilyn Stovall; Yutaka Yasui Journal: J Clin Oncol Date: 2009-04-13 Impact factor: 44.544
Authors: Ilse A J van Rooij; Isolde den Tonkelaar; Frank J M Broekmans; Caspar W N Looman; Gabrielle J Scheffer; Frank H de Jong; Axel P N Themmen; Egbert R te Velde Journal: Menopause Date: 2004 Nov-Dec Impact factor: 2.953
Authors: D M Greenfield; E Boland; Y Ezaydi; R J M Ross; S H Ahmedzai; J A Snowden Journal: Bone Marrow Transplant Date: 2014-04-07 Impact factor: 5.483
Authors: Brigitte Gerstl; Elizabeth Sullivan; Jana Koch; Handan Wand; Angela Ives; Richard Mitchell; Nada Hamad; Antoinette Anazodo Journal: Support Care Cancer Date: 2019-09-21 Impact factor: 3.603
Authors: Simone Reinmuth; Cynthia Hohmann; Rosa Rendtorff; Magdalena Balcerek; Steve Holzhausen; Andreas Müller; Günter Henze; Thomas Keil; Anja Borgmann-Staudt Journal: J Cancer Res Clin Oncol Date: 2013-10-02 Impact factor: 4.553
Authors: Helena Mörse; Maria Elfving; Aleksandra Turkiewicz; Claus Yding Andersen; Ingrid Øra Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889